An updated protocol for evaluating chest pain and managing acute coronary syndromes

Critical Pathways in Cardiology

Volumn 16, Issue 1, 2017, Pages 7-14

  Kelly, Christopher R ^a   Kirtane, Ajay J ^a   Stant, Jennifer ^a   Stone, Gregg W ^a   Minutello, Robert M ^b   Wong, S Chiu ^b   Manuzon, Honeyleen ^a   Gerow Smith, Roxanne ^a   Kelley, Nancy ^a   Rabbani, LeRoy E ^a  

^a NewYork Presbyterian Hospital   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndromes; Antiplatelet therapy; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BRAIN NATRIURETIC PEPTIDE; CANGRELOR; CLOPIDOGREL; CREATINE KINASE MB; METOPROLOL; PRASUGREL; TICAGRELOR; TROPONIN; WARFARIN;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS GRAFT; DUAL ANTIPLATELET THERAPY; ELECTROCARDIOGRAPHY; HEART INFARCTION; HUMAN; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THORAX PAIN; UNSTABLE ANGINA PECTORIS; CHEST PAIN; CLINICAL PATHWAY; COMPLICATION; DISEASE MANAGEMENT;

ACUTE CORONARY SYNDROME; CHEST PAIN; CRITICAL PATHWAYS; DISEASE MANAGEMENT; HUMANS;

EID: 85013678459     PISSN: 1535282X     EISSN: 15352811     Source Type: Journal    
DOI: 10.1097/HPC.0000000000000098     Document Type: Article

References (31)

1. Rosner GF, Stone GW, Stant J, et al. Updating an institutional chest pain algorithm: Incorporating new evidence on emerging pharmacotherapy. Crit Pathw Cardiol. 2012; 11: 107-113.
2. Lilly LS. Pathophysiology of Heart Disease: A Collaborative Project of Medical Students and Faculty. 5th ed. Baltimore, MD: Wolters Kluwer/Lippincott Williams & Wilkins; 2011.
3. Yusuf S, Zhao F, Mehta SR, et al; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494-502.
4. Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001-2015.
5. Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361: 1045-1057.
6. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study. Circulation. 2009; 120: 2577-2585.
7. Wiviott SD, Trenk D, Frelinger AL, et al; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading-And maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007; 116: 2923-2932.
8. Heestermans AA, van Werkum JW, Taubert D, et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res. 2008; 122: 776-781.
9. Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012; 5: 797-804.
10. Parodi G, Bellandi B, Xanthopoulou I, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv. 2015; 8: E001593.
11. Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: Results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011; 57: 672-684.
12. Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology, American Heart Association Task Force on Practice Guidelines, Society for Cardiovascular Angiography, Interventions and Society of Thoracic Surgeons, American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 64: E139-228.
13. Fan W, Plent S, Prats J, Deliargyris EN. Trends in P2Y12 inhibitor use in patients referred for invasive evaluation of coronary artery disease in contemporary US practice. Am J Cardiol. 2016; 117: 1439-1443.
14. Bellemain-Appaix A, O'Connor SA, Silvain J, et al; ACTION Group. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: A systematic review and meta-Analysis. JAMA. 2012; 308: 2507-2516.
15. Montalescot G, Bolognese L, Dudek D, et al; ACCOAST Investigators. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013; 369: 999-1010.
16. Montalescot G, van 't Hof AW. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014; 371: 2339.
17. Temple R. NDA approval letter: Kengreal (cangrelor NDA 204958). Available at: Http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2015/204958Ori g1s000ltr.pdf. Accessed November 2016.
18. Bhatt DL, Lincoff AM, Gibson CM, et al; CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009; 361: 2330-2341.
19. Bhatt DL, Stone GW, Mahaffey KW, et al; CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013; 368: 1303-1313.
20. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009; 361: 2318-2329.
21. Schneider DJ, Agarwal Z, Seecheran N, et al. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc Interv. 2014; 7: 435-442.
22. Steinhubl SR, Oh JJ, Oestreich JH, et al. Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect. Thromb Res. 2008; 121: 527-534.
23. Schneider DJ, Seecheran N, Raza SS, et al. Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coron Artery Dis. 2015; 26: 42-48.
24. Dovlatova NL, Jakubowski JA, Sugidachi A, et al. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost. 2008; 6: 1153-1159.
25. Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med. 2010; 362: 1374-1382.
26. Collet JP, Silvain J, Barthélémy O, et al; ARCTIC investigators. Dualantiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): A randomised trial. Lancet. 2014; 384: 1577-1585.
27. Mauri L, Kereiakes DJ, Yeh RW, et al; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014; 371: 2155-2166.
28. Yeh RW, Kereiakes DJ, Steg PG, et al; DAPT Study Investigators. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol. 2015; 65: 2211-2221.
29. Bonaca MP, Bhatt DL, Cohen M, et al; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-Term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372: 1791-1800.
30. Yeh RW, Secemsky EA, Kereiakes DJ, et al; DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016; 315: 1735-1749.
31. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2016; 152: 1243-1275.